Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: Comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel

Medical Oncology

Volumn 26, Issue 2, 2009, Pages 124-130

  Rubenstein, Marvin ^a,b,c   Tsui, Paulus ^a,c   Guinan, Patrick ^a,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Breast cancer; Paclitaxel; Prostate cancer; Rapamycin; Therapy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN BCL 2; RAPAMYCIN; TRANSFORMING GROWTH FACTOR ALPHA; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS REGULATORY PROTEIN;

ARTICLE; BINDING SITE; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL STRAIN LNCAP; CELL STRAIN MCF 7; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; PRIORITY JOURNAL; PROSTATE TUMOR; SIGNAL TRANSDUCTION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENE TARGETING; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 67651034609     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9088-5     Document Type: Article

References (17)

1. M Rubenstein P Tsui P Guinan 2005 Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors Med Hypotheses 65 905 7 10.1016/j.mehy.2004.12.032 16023790 10.1016/j.mehy.2004.12.032 1:CAS:528:DC%2BD2MXptVeks7c%3D
2. M Rubenstein P Tsui P Guinan 2006 Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy Methods Find Clin Pharmacol 28 515 8 10.1358/mf.2006.28.8.1003571 10.1358/mf.2006.28.8.1003571 1:CAS:528: DC%2BD2sXisVSntA%3D%3D (Pubitemid 44885380)
3. M Rubenstein P Tsui P Guinan 2007 Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors Med Oncol 24 189 96 10.1007/BF02698039 17848743 10.1007/BF02698039 1:CAS:528:DC%2BD2sXpsVKls7Y%3D (Pubitemid 350135970)
4. M Rubenstein P Tsui P Guinan 2007 Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate cancer Med Oncol 24 372 8 10.1007/s12032-007-0023-y 17917084 10.1007/s12032-007-0023-y 1:CAS:528:DC%2BD2sXhtlerur3F (Pubitemid 350135928)
5. M Rubenstein P Tsui P Guinan 2008 Treatment of MCF-7 breast cancer cells employing monospecific and bispecific antisense oligonucleotides having binding specificity towards proteins associated with autocrine regulated growth and bcl-2 Med Oncol 25 182 6 10.1007/s12032-007-9018-y 17972023 10.1007/s12032-007- 9018-y 1:CAS:528:DC%2BD1cXotVOgtbo%3D
6. Weinberg RA. The biology of cancer. In: Weinberg RA, editor. 16.15 mTOR, a master regulator of cell physiology, represents an attractive target for anti-cancer therapy. Garland Science, Taylor and Francis Group, LLC; 2007. p. 782-7.
7. DM Sabatini 2006 mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 729 34 10.1038/nrc1974 16915295 10.1038/nrc1974 1:CAS:528:DC%2BD28XosVOmsb8%3D (Pubitemid 44286004)
8. RJ Shaw LC Cantley 2006 Ras, PI(3)K, and mTOR signaling controls tumour cell growth Nature 441 424 30 10.1038/nature04869 16724053 10.1038/nature04869 1:CAS:528:DC%2BD28XkvVyrsr8%3D (Pubitemid 44050136)
9. P Amornphimoltham V Patel K Leelahavanichkul RT Abraham JS Gutkind 2008 A retroinhibition approach reveals a tumor cell-autonomous response to Rapamycin in head and neck cancers Cancer Res 68 1144 53 10.1158/0008-5472.CAN-07-1756 18281490 10.1158/0008-5472.CAN-07-1756 1:CAS:528:DC%2BD1cXhvFemur4%3D (Pubitemid 351272233)
10. NJ Sanfilippo SS Taneja A Chachoua H Lepor SC Formenti 2008 Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer J Clin Oncol 26 2973 8 10.1200/JCO.2007.14.4105 18565883 10.1200/JCO.2007.14.4105 1:CAS:528:DC%2BD1cXoslOqsL4%3D
11. M Gleave A Tolcher H Miyake C Nelson B Brown E Beraldi J Goldie 1999 Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model Clin Cancer Res 5 2891 8 10537358 1:CAS:528:DyaK1MXntlGluro%3D
12. M Rubenstein L Slobodskoy Y Mirochnik P Guinan 2003 Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol Med Oncol 20 29 35 10.1385/MO:20:1:29 12665682 10.1385/MO:20:1:29 1:CAS:528:DC%2BD3sXjtVeltLs%3D (Pubitemid 36344023)
13. P Tsui M Rubenstein P Guinan 2004 Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model Med Oncol 21 339 48 10.1385/MO:21:4:339 15579918 10.1385/MO:21:4:339 1:CAS:528:DC%2BD2MXktlGitA%3D%3D (Pubitemid 40065485)
14. M Rubenstein KM Anderson P Tsui P Guinan 2006 Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer Med Hypotheses 67 1374 9 10.1016/j.mehy.2006.05.055 10.1016/j.mehy.2006.05.055 (Pubitemid 44442657)
15. A Janus T Robak P Smolewski 2005 The mammalian target of the Rapamycin (mTOR) kinase pathway; its role in tumourigenesis and target antitumour therapy Cell Mol Biol Lett 10 479 97 16217558 1:CAS:528:DC%2BD2MXht1ehsrrJ
16. CC Hudson M Liu GG Chiang DM Otterness DCKaper F Loomis F Kaper AJ Giaccia RT Abraham 2002 Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of Rapamycin Mol Cell Biol 22 7004 14 10.1128/MCB.22.20.7004-7014.2002 12242281 10.1128/MCB.22.20.7004-7014. 2002 1:CAS:528:DC%2BD38XnsFKitrk%3D
17. MB Atkins MK Hidalgo WM Stadler TF Logan JP Dutcher GR Hudes Y Park SH Liou B Marshall JP Boni G Dukart ML Sherman 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 18 10.1200/JCO.2004.08.185 14990647 10.1200/JCO.2004.08.185 1:CAS:528:DC%2BD2cXpsVKisr0%3D (Pubitemid 41103603)